Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07420348

Incidence of Ultrasonographically Detected Articular Damage in Initially Healthy Joints of Patients With Hemophilia A Receiving Prophylactic Treatment With Emicizumab

Introduction: Prophylaxis with emicizumab has substantially improved hemorrhagic control in hemophilia A. However, the longitudinal incidence of ultrasonographically detected articular damage in initially healthy joints remains insufficiently characterized.

Objective: To estimate the incidence of ultrasonographically detected articular damage in initially healthy joints among patients with hemophilia A receiving prophylaxis with emicizumab and to explore its association with relevant clinical variables.

Methods: A prospective, longitudinal, observational study will be conducted in approximately 70 patients with hemophilia A receiving emicizumab, with an estimated recruitment of approximately 270 initially healthy joints. The study is purely observational and does not involve evaluation of the investigational product nor modification of the therapeutic regimen; dosing, administration intervals, and all clinical decisions regarding emicizumab will be determined exclusively at the discretion of the treating hematologist. Assessments will be performed at baseline and at 12 and 24 months. The unit of analysis will be the joint, including elbows, knees, and ankles without ultrasonographic evidence of articular damage and without a history of clinically evident hemarthrosis at study entry.

The primary endpoint will be the occurrence of incident ultrasonographically detected articular damage, assessed using the Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) protocol. Secondary outcomes will include clinical joint health assessed by the Hemophilia Joint Health Score (HJHS), version 2.1; the frequency of joint hemarthroses measured by the annualized joint bleeding rate (AJBR); and habitual physical activity levels evaluated through age-specific validated questionnaires. Statistical analyses will account for intra-patient correlation among joints.

Expected Results: A low to moderate incidence of ultrasonographically detected articular damage in initially healthy joints is anticipated during follow-up, providing clinically relevant information regarding structural joint preservation in patients with hemophilia A receiving emicizumab prophylaxis.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

10 year and older

Sex eligibility

Male

Study type

Observational

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Confirmed diagnosis of hemophilia A;
  • Receiving prophylactic treatment with emicizumab (Hemlibra®) according to routine clinical practice;
  • Age ≥10 years at the time of study enrollment;
  • Absence of ultrasonographic joint damage in at least one of the evaluated joints (elbows, knees, or ankles), defined as HEAD-US = 0 at baseline assessment;
  • No documented history of clinically evident hemarthrosis in the corresponding joints from initiation of emicizumab prophylaxis to the study baseline evaluation;
  • Ability to understand and complete study procedures (interviews, questionnaires, and clinical assessments), in accordance with the participant's age; and
  • Provision of written informed consent; for minors, written informed consent from parents or legal guardians and assent from the minor participant, in accordance with applicable regulations.

Exclusion criteria

  • Presence of ultrasonographic joint damage (HEAD-US ≥1) in all evaluated joints at the baseline visit;
  • Documented history of clinically evident hemarthrosis in the joints under study;
  • Prior major orthopedic surgery or arthroplasty in the evaluated joints;
  • Presence of concomitant musculoskeletal pathology unrelated to hemophilia that could interfere with joint assessment (e.g., inflammatory arthritis, recent severe trauma);
  • Inability to complete the planned 24-month follow-up or to undergo study assessments;
  • Concurrent participation in another interventional study that could interfere with the joint health variables under evaluation; and
  • Any clinical or social condition that, in the investigator's judgment, could compromise participant safety or the validity of the study data.

Treatment and study plan

Hemophilia patients

Other

A prospective, longitudinal, observational study will be conducted in patients with hemophilia A receiving prophylaxis with emicizumab, with a 24-month follow-up period. Three assessments will be performed: at baseline, 12 months, and 24 months.

Primary outcomes

  1. Measurement of Ultrasonographically Detected Articular Damage in Elbows, Knees, and Ankles

    Time frame: Baseline visit, at 12 months, and at 24 months.

    Ultrasonographically detected articular damage will be assessed using the Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) protocol through standardized musculoskeletal ultrasound examination. This scoring system evaluates three structural domains per joint: synovial (hypertrophy and effusion), cartilage, and bone. Each joint is assigned an ordinal score ranging from 0 (no abnormalities) to a maximum of 8 points, derived from the combined assessment of the synovial, cartilaginous, and osseous domains. The HEAD-US protocol enables detection of subclinical joint damage and early structural changes, even in the absence of clinically evident hemarthrosis.Scree

Secondary outcomes

  1. Measurement of Clinical Joint Health in Knees, Ankles, and Elbows

    Time frame: Baseline visit, at 12 months, and at 24 months.

    Clinical joint health will be assessed using the Hemophilia Joint Health Score, version 2.1 (HJHS 2.1). This instrument evaluates eight items per joint: swelling (edema), duration of swelling, pain, muscle atrophy, crepitus, strength deficit, loss of range of motion, and joint deformity. Additionally, it includes a global gait assessment scored from 0 to 4. Each item is rated on an ordinal scale according to the instrument's predefined criteria, yielding a per-joint score ranging from 0 to 20 and a total score ranging from 0 to 124. Higher scores indicate worse clinical joint health.

  2. Measurement of Joint Hemorrhagic Phenotype

    Time frame: Baseline visit, at 12 months, and at 24 months.

    This variable will be assessed using the Annualized Joint Bleeding Rate (AJBR), calculated as the number of hemarthroses occurring during the observation period divided by the total days of follow-up and multiplied by 365.25. The AJBR will be calculated both globally and on a per-joint basis, based on systematically recorded bleeding events obtained through structured clinical interviews.

  3. Measurement of Physical Activity Level in patients under 18 years of age

    Time frame: Baseline visit, at 12 months, and at 24 months.

    This variable will be assessed using the Physical Activity Questionnaire for Adolescents (PAQ-A). The PAQ-A consists of nine items evaluating participation in various types of physical and sports activities; frequency of activity during physical education classes; activity during recess and leisure time; after-school activity; weekend activity; and overall level of habitual physical activity. Each item is scored on a 5-point Likert scale (1 to 5), and the final score corresponds to the mean of all items. Higher scores indicate a greater level of habitual physical activity.

  4. Measurement of Physical Activity Level in Adult Patients

    Time frame: Baseline visit, at 12 months, and at 24 months.

    This variable will be assessed using the International Physical Activity Questionnaire - Long Form (IPAQ-LF). The IPAQ-LF captures physical activity across four domains: work-related physical activity, active transportation, domestic and household activities, and leisure-time physical activity. Within each domain, the time spent in vigorous-intensity activity, moderate-intensity activity, and walking is recorded, allowing for the calculation of total energy expenditure expressed in MET-minutes per week (MET-min/week).

  5. Measurement of Treatment Adherence

    Time frame: Baseline visit, at 12 months, and at 24 months.

    This variable will be assessed using the Torres questionnaire for treatment adherence in hemophilia. This hemophilia-specific instrument evaluates five dimensions: disease awareness, perceived sequelae, treatment-related difficulties, physician-patient relationship, and hemorrhagic processes. Higher scores indicate greater adherence within the corresponding domain.

Other outcomes

  1. Measurement of Age

    Time frame: Screening visit

    This variable, used to describe the sample and control for potential confounding factors, will be measured as a quantitative variable (in years)

  2. Measurement of Hemophilia Severity

    Time frame: Screening visit

    This variable, used to describe the sample and control for potential confounding factors, will be measured as an ordinal variable (severe / moderate / mild).

  3. Measurement of Inhibitor Status

    Time frame: Screening visit

    This variable, used to describe the sample and control for potential confounding factors, will be measured as a dichotomous variable (yes / no)

  4. Measurement of Duration of Emicizumab Prophylaxis

    Time frame: Screening visit

    This variable, used to describe the sample and control for potential confounding factors, will be measured as a quantitative variable (in years).

Study contacts

Contact information is provided by the study sponsor or research team.

Rubén Cuesta-Barriuso, PhD

CONTACT

[email protected]

0034 985103386

Sponsors and collaborators

Lead sponsor

Investigación en Hemofilia y Fisioterapia

Network

Registry information

Official study title

Incidence of Ultrasonographically Detected Articular Damage in Initially Healthy Joints of Patients With Hemophilia A Receiving Prophylactic Treatment With Emicizumab. A Prospective Observational Study

Important dates

Study start
2026
Primary completion
2026
Study completion
2028
First posted
Feb 19, 2026
Registry last updated
Feb 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.